Clinical trials: Condyloma Acuminata
HPV Infections, Cervical Cancer
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese females aged 9 to 45 years
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT04895020
- Testing
- 9-valent HPV vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Vulvar Cancer
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
The purpose of this study is to evaluate the safety and immunogenicity of V505 in comparison to GARDASIL (TM)
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00520598
- Testing
- Comparator: V505 formulation 1, Comparator: V505 formulation 2, Comparator: V505 formulation 3
- Volunteers
- 511 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Warts Hand, Wart, Genital
Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts
In the present study the investigators assessed the invitro role of IL-4 and IFN-γ in predicting the response to bivalent HPV vaccine after whole blood stimulation
- Trial name
- NCT05100043
- Testing
- IL-4 and IFN-γ measurements
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Zagazig University
Wart, Genital
Cantharone for the Treatment of Perenial Warts
Comparison of trichloroacetic acid versus cantharidine for the treatment of perenial warts.
- Trial name
- NCT03625960
- Testing
- Cantharidin, Trichloroacetic Acid
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Wayne State University
Condylomata Acuminata
Carbon Dioxide Laser vs. Electrocoagulation for the Therapy of Condyloma
In a randomized clinical trial of 114 women undergoing Treatment for condyloma acuminata, two surgical methods, the carbon dioxide laser Ablation and the excision by electrocoagulation, will be compared.
- Trial name
- NCT02520986
- Testing
- Carbon dioxide Laser ablation, Electrocoagulation
- Where
- Germany
- Volunteers
- 140 people
- Sponsor
- Ruhr University of Bochum
Genital Warts
Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW.
- Trial name
- NCT00735462
- Testing
- 2.5% imiquimod cream, 3.75% imiquimod cream
- Where
- 43 sites in United States
- Volunteers
- 511 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Cervical Intraepithelial Neoplasia, Cervical Cancer
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
This phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD.…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Condylomata Acuminata
- Trial name
- NCT04537156
- Testing
- Nonavalent HPV vaccine, Bivalent HPV vaccine
- Where
- 2 sites in China
- Volunteers
- 9,327 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Cervical Cancers, Vulvar Cancer
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
To evaluate the safety and immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years.
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT03676101
- Testing
- 9-valent HPV Recombinant Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Genital Warts
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
The primary purpose of the study is to determine if an investigational vaccine Gardasil (V501) with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents.
- Trial name
- NCT00092495
- Testing
- V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 3,055 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Condyloma, Genital Warts
Effectiveness Study of Gardasil on Condyloma
Overview and rationale: Through Swedish health care registers it is possible vaccine effectiveness. The overall aim is to develop tools for fast and reliable evaluation of vaccines focusing on effectiveness.
- Trial name
- NCT01553994
- Where
- Sweden
- Volunteers
- 500,000 people, healthy volunteers welcome
- Sponsor
- Lisen Arnheim Dahlstrom
Genital Warts, Human Papilloma Virus
Typing of Human Papilloma Virus (HPV) From Female Genital Warts
This is a longitudinal observational study of women presenting to Groote Schuur Hospital with genital warts. The study will evaluate the socio-demographic characteristics of the women using a structured questionnaire.
- Trial name
- NCT01192282
- Testing
- Medical / Surgical Treatment
- Where
- South Africa
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- University of Cape Town
Anogenital Wart
Topical Ethanol Extract (Piper Crocatum) for Anogenital Warts
This clinical trial aims to assess the efficacy of topical Piper crocatum in treating Anogenital warts. It aims to answer the clinical efficacy of treating anogenital warts the expression of Foxp3+ regulatory T (Treg), TGF/Tumor…
- Trial name
- NCT05622916
- Testing
- Topical Ethanol Extract (Piper crocatum), Trichloroacetic Acid Topical
- Where
- Indonesia
- Volunteers
- 100 people
- Sponsor
- Hasanuddin University
Genital Warts, HPV Infections
Human Papillomavirus (HPV) Genotypes in Genital Warts in Colombian Population
HPV infection has been recognized as the most prevalent sexual transmitted infection worldwide. Burden of many HPV related diseases is well known particularly regarding the different associated cancers (cervical, anal, vaginal…
- Trial name
- GWprofamilia (NCT00847340)
- Testing
- Biopsy Excisional
- Volunteers
- 342 people
- Sponsor
- La Fundacion para la Investigacion y el Desarrollo
Cervical Cancer, Genital Warts
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
The purpose of the study is to determine if an investigational vaccine with a single component develops an immune response that is similar to the equivalent investigational vaccine with four components to reduce cervical disease.
- Trial name
- NCT00092482
- Testing
- V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years
- Volunteers
- 3,882 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus, Warts
Intralesional HPV Vaccine for Condylomata
This study will investigate whether injecting genital warts with small quantities of the Gardasil 9 vaccine has an effect on the warts.
- Conditions
- Human Papilloma Virus, Warts, Warts, Genital, Condyloma
- Trial name
- NCT05087849
- Testing
- nonavalent human papillomavirus vaccine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Condylomata Acuminata (External)
Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts
The purpose of this study is to assess the pharmacodynamics, safety and efficacy of omiganan in patients with external genital warts.
- Trial name
- NCT02849262
- Testing
- Omiganan (CLS001) topical gel, Vehicle topical gel
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.
Papillomavirus Infections, Uterine Cervical Neoplasms
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
This study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam.
- Conditions
- Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms
- Trial name
- NCT03546842
- Testing
- 9vHPV vaccine
- Where
- Vietnam
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Vulvar Cancer
Education, Immigration and HPV Vaccination: an Informational Randomized Trial
Counteracting misinformation on childhood vaccines remains a priority for public health in industrialized countries. Previous research showed that misinformation-induced vaccine hesitancy particularly concerns very highly or very…
- Conditions
- Cervical Cancer, Vulvar Cancer, Anus Cancer, Penis Cancer
- Trial name
- NCT04905030
- Testing
- Information T1, Information T2, Information C
- Where
- Sweden
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Female Genital Warts
The Psychosocial and Economic Burden of Genital Warts
Considering the importance of HPV(human papilomavirus) and related diseases in Brazil, and the lack of studies about both the economic and the psychosocial burden of these diseases, BEMFAM, a Brazilian non-governmental…
- Trial name
- GWburden (NCT01520194)
- Testing
- women attending reproductive health clinics, medical records
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- BEMFAM-Bem Estar Familiar
Human Papillomavirus Infection, Anogenital Warts
Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts
The primary purpose of this study is to evaluate the effectiveness of destructive therapy for anogenital warts in combination with the use of Ingaron in comparison with destructive therapy.
- Trial name
- ING-HPV-1 (NCT05156541)
- Testing
- Interferon gamma human recombinant (IFN-G)
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- SPP Pharmaclon Ltd.